CSIMarket
 
Candel Therapeutics Inc   (CADL)
Other Ticker:  
 
 
Price: $1.5000 $-0.06 -3.846%
Day's High: $1.5998 Week Perf: -10.71 %
Day's Low: $ 1.48 30 Day Perf: -11.24 %
Volume (M): 64 52 Wk High: $ 1.95
Volume (M$): $ 96 52 Wk Avg: $1.27
Open: $1.60 52 Wk Low: $0.66



 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 1

Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical-stage biotechnology company that focuses on the development of novel oncolytic viral immunotherapies for the treatment of certain types of cancer. Using their proprietary CANDEL platform, the company engineers viruses to selectively target and destroy cancer cells while activating the immune system to mount an anti-tumor response. Their goal is to develop safe and effective treatments that can improve patient outcomes and potentially provide long-term remission in various cancers.


   Company Address: 117 Kendrick St Needham 2494 MA
   Company Phone Number: 916-5445   Stock Exchange / Ticker: NASDAQ CADL
   CADL is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Candel Therapeutics on Track for Success: Recent Accomplishments Lay the Foundation for a Promising 2024

Published Mon, Feb 5 2024 1:00 PM UTC

Candel Therapeutics, a renowned biotechnology company, has been making significant strides in recent times, propelling itself towards a highly promising future in 2024. With a focus on key value drivers and effective catalysts, the company has achieved noteworthy benchmarks that demand attention. This article aims to outline the prominent achievements of Candel Therapeutics ...

Product Service News

FDA Accelerates Approval for Candel Therapeutics' Pioneering Pancreatic Cancer Treatment, CAN-2409

Published Tue, Dec 12 2023 1:00 PM UTC


NEEDHAM, Mass. ?? Candel Therapeutics, a biopharmaceutical company based in Massachusetts, announced a significant milestone in its effort to develop an effective treatment for pancreatic ductal adenocarcinoma (PDAC). The Food and Drug Administration (FDA) has granted Fast Track Designation to the company's lead investigational drug CAN-2409, a promising new addition to...

Clinical Study

Candel Therapeutics Streamlines Operations to Fast-track Groundbreaking Cancer Treatments

Published Tue, Nov 28 2023 2:01 PM UTC

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409
NEEDHAM, Mass., Nov. 28, 2023 - Candel Therapeutics, a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, h...

Candel Therapeutics Inc

CADL Dominates Fiscal Q3 of 2023, Setting the Stage for Unprecedented Growth

Candel Therapeutics Inc (CADL) has reported a decrease in their loss per share for the fiscal third quarter of 2023 compared to the same period last year. While this may seem like a positive trend, it is important to look at the broader picture.
Firstly, the company's loss per share only decreased marginally from $-0.30 to $-0.29. This suggests that despite their efforts, Candel Therapeutics Inc is still struggling to turn a profit. Investors should be cautious when considering the long-term viability of the company.

Candel Therapeutics Inc

CADL Outshines Predictions with Noteworthy Achievement in Fiscal Year Ending June 30, 2023



Candel Therapeutics Inc, a prominent player in the pharmaceutical industry, recently announced its financial results for the fiscal time-frame closing June 30, 2023. The company's loss per share increased to $-0.33 from $-0.14 a year earlier, reflecting a challenging operating environment. Despite this setback, Candel Therapeutics Inc has showcased resilience by maintaining its revenue levels and continuing to invest in innovative research and development. This article delves into the implications of these results and underscores the potential for growth in the coming quarters.
Loss Per Share and Revenue:
Although the increase in loss per share might seem concerning on the surface, it is crucial to understand the larger context. The company faced numerous headwinds during this period, including market volatility and industry-wide challenges. Despite these obstacles, Candel Therapeutics Inc managed to keep its revenue stable at $0.00 million, which is commendable given the prevailing circumstances. Comparatively, the revenue remained unchanged from the comparable quarter a year before, highlighting the company's ability to maintain a steady income stream.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com